107 related articles for article (PubMed ID: 12171044)
1. Drug giant Bristol-Myers Squibb: Atazanavir moves into the spotlight while O83 bites the dust.
Posit Aware; 2002; 13(4):42-3. PubMed ID: 12171044
[No Abstract] [Full Text] [Related]
2. Effect of baseline protease genotype and phenotype on HIV response to atazanavir/ritonavir in treatment-experienced patients.
Naeger LK; Struble KA
AIDS; 2006 Apr; 20(6):847-53. PubMed ID: 16549968
[TBL] [Abstract][Full Text] [Related]
3. [New protease inhibitor atazanavir. Simple administration--less resistance].
MMW Fortschr Med; 2002 Aug; 144(31-32):47. PubMed ID: 12422733
[No Abstract] [Full Text] [Related]
4. Bristol-Myers Squibb drug information department services.
Sylvan L; Palmer-Shevlin N
Hosp Pharm; 1995 Jan; 30(1):38-9, 44. PubMed ID: 10139729
[TBL] [Abstract][Full Text] [Related]
5. FDA notifications. Atazanavir capsule label is updated for pediatric patients.
AIDS Alert; 2008 May; 23(5):59-60. PubMed ID: 18637262
[No Abstract] [Full Text] [Related]
6. Merck, Bristol-Myers Squibb announce major price reductions for poorest countries: major access progress but questions remain.
James JS
AIDS Treat News; 2001 Feb; (361):5-7. PubMed ID: 12765151
[TBL] [Abstract][Full Text] [Related]
7. Norvir hangover.
Clifton CE
Posit Aware; 2004; 15(2):7-9. PubMed ID: 15106524
[No Abstract] [Full Text] [Related]
8. Atazanavir.
Orrick JJ; Steinhart CR
Ann Pharmacother; 2004 Oct; 38(10):1664-74. PubMed ID: 15353575
[TBL] [Abstract][Full Text] [Related]
9. Reyataz dosing options discussed. Excerpts from the FDA atazanavir hearing.
Huff B
GMHC Treat Issues; 2003 Jun; 17(6):8-11. PubMed ID: 12913962
[No Abstract] [Full Text] [Related]
10. [Simplified HIV therapy. Atazanavir: the first protease inhibitor with once daily administration].
MMW Fortschr Med; 2004 Apr; 146 Spec No 1():14-6. PubMed ID: 15373035
[No Abstract] [Full Text] [Related]
11. [Atazanavir protects lipid metabolism. New PI with favorable metabolic profile].
MMW Fortschr Med; 2004 Apr; 146 Spec No 1():90. PubMed ID: 15373065
[No Abstract] [Full Text] [Related]
12. FDA notifications. BMS issues letter about omeprazole.
AIDS Alert; 2005 Apr; 20(4):45-6. PubMed ID: 15841529
[No Abstract] [Full Text] [Related]
13. [Maintaining independence. New protease inhibitor receives drug approval recommendation].
MMW Fortschr Med; 2004 Apr; 146 Spec No 1():84-5. PubMed ID: 15373062
[No Abstract] [Full Text] [Related]
14. Impact of HIV protease inhibitor resistance in treatment-naive populations in the united states.
Hicks C
AIDS Read; 2005 Dec; 15(12):683-6, 689-90. PubMed ID: 16355598
[TBL] [Abstract][Full Text] [Related]
15. FDA notifications. Revised atazanavir package insert.
AIDS Alert; 2008 Mar; 23(3):35-6. PubMed ID: 18661642
[No Abstract] [Full Text] [Related]
16. Anti-HIV agents. Atazanavir as a booster for protease inhibitors.
TreatmentUpdate; 2003; 15(4):1-2. PubMed ID: 17216850
[No Abstract] [Full Text] [Related]
17. FDA notifications. Abbott sends out provider letter about Kaletra for kids.
AIDS Alert; 2007 Oct; 22(10):118. PubMed ID: 18416010
[No Abstract] [Full Text] [Related]
18. Deal watch: Bristol-Myers Squibb and Exelixis collaborate on kinase inhibitors.
Nat Rev Drug Discov; 2009 Feb; 8(2):98. PubMed ID: 19180098
[No Abstract] [Full Text] [Related]
19. Atazanavir-associated nephrolithiasis: cases from the US Food and Drug Administration's Adverse Event Reporting System.
Chan-Tack KM; Truffa MM; Struble KA; Birnkrant DB
AIDS; 2007 May; 21(9):1215-8. PubMed ID: 17502736
[TBL] [Abstract][Full Text] [Related]
20. FDA notifications. Alternative dosing regimen for atazanavir is approved.
AIDS Alert; 2008 Nov; 23(11):129-30. PubMed ID: 19048649
[No Abstract] [Full Text] [Related]
[Next] [New Search]
